Daniel Slade

Blockade of MCU-Mediated Ca2+ Uptake Perturbs Lipid Metabolism via PP4-Dependent AMPK Dephosphorylation

Dhanendra Tomar, Fabián Jaña, Zhiwei Dong et al. · Cell Reports · 2019 · 95 citations · Full text

Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia

Charles Craddock, Daniel Slade, Carmela De Santo et al. · Journal of Clinical Oncology · 2019 · 71 citations · Full text

Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

Tonny Veenith, Daniel Slade, Charlotte Gaskell et al. · UCL Discovery (University College London) · 2022 · 57 citations

Disease Management, Proof-of-concept Trial, Symptomatic Treatment +7

Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial

Mhairi Copland, Daniel Slade, Graham McIlroy et al. · The Lancet Haematology · 2021 · 51 citations

Phase 1/2, Hematological Malignancy, Oncology +7

Do we need to adjust for interim analyses in a Bayesian adaptive trial design?

Elizabeth Ryan, Kristian Brock, Simon Gates et al. · BMC Medical Research Methodology · 2020 · 44 citations · Full text